About the Study

The Polycystic Kidney Disease Treatment Network (PKD-TN) has developed the HALT PKD clinical trials to evaluate certain FDA approved drugs that may be effective in slowing kidney growth in persons who have polycystic kidney disease. Seven centers across the United States are participating in the two trials.

Click here to read more.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Testimonial

Alan found out he had polycystic kidney disease around 5 years ago. He has generously agreed to share his story for us.

I had never heard of Polycystic Kidney Disease until about five years ago when an MRI revealed spots proliferating my kidneys and liver. I was 45 and the cause of my stomach trouble leading to these tests had nothing to do with the PKD they discovered. The big fear was cancer so when we reviewed an autopsy that had been performed on my father and found that he had PKD, it was actually a minor relief.

Click here to read more.


Nutritional Corner by Kelly Welsh, R.D, C.D.

this months recipe is Roasted Corn and Edamame Salad, click here to read more.

About the Study

The Polycystic Kidney Disease Treatment Network (PKD-TN) has developed the HALT PKD clinical trials to evaluate certain FDA approved drugs that may be effective in slowing kidney growth in persons who have polycystic kidney disease. Seven centers across the United States are participating in the two trials. Financial support of the study is provided by the NIH National Institute of Diabetes & Digestive & Kidney Diseases and the PKD Foundation. Study medications are provided by Boehringer Ingleheim and Merck.

The studies recruited both male and female participants between the ages of 15 and 64. The two multicenter randomized clinical trials targeted different levels of kidney function. Study A: early disease defined by GFR >60 mL/min/1.73 m2 and Study B: moderately advanced disease defined by GFR 25-60 mL/min/1.73 m2.

Participants enrolled in Study A will be followed for a total of four years, while those enrolled in Study B will be followed for four-to-six years, with the average length of follow-up being five years. The two concurrent randomized clinical trials differ by eligibility criteria, interventions and outcomes to be studied.

Primary Outcome Measures: